Navigation Links
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
Date:5/17/2010

t designation provides the sponsor with access to the Centralized Procedure for the application for marketing authorization, protocol assistance, up to a 100% reduction in fees related to a marketing authorization application, pre-authorization inspection and post-authorization activities, and could provide ten years of market exclusivity in EU, once approved for the treatment of ovarian cancer.

About Ovarian Cancer

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... research report on the transformer market. The report ... and industry chain structure as well as industry ... including China’s domestic market as well as global ... analysis. The report also covers information on policy, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori ... CEO Marc Hedrick , M.D. will present live at ... December 4, 2014 TIME:    11:15 am PT / ... paste this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... save time and receive event updates. This ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
(Date:11/18/2014)... San Diego, CA (PRWEB) November 17, 2014 ... Emerson of Salk , Dr. Beverly Emerson, a professor in ... behavior of genes. Her most recent discovery points to an ... about Dr. Emerson’s career and how her local research is ... Emerson will present her findings and then join host Cheryl ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... International Corporation (NASDAQ: PRXL ) announced today that ... in New York.  Josef von Rickenbach, Chairman and Chief Executive ... p.m.  ET on Wednesday, September 7, 2011.   ... Growth Stock Conference in New York.  Josef von Rickenbach, Chairman ...
... Savvier consumers and competition from generic drugs have made ... maturity, more elusive.  At the same time, new technologies ... to support pharmaceutical brand growth. While biopharma ... brands, recent field research from Best Practices, LLC suggests ...
... manufacturer of advanced cell imaging systems, today announced that the ... division of Merck KGaA of Germany.  The transaction is subject ... in the fourth quarter of 2011. The terms of the ... of USD 14 million (EUR 10 million) in 2010 and ...
Cached Biology Technology:PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference 2Using Public Relations to Launch, Grow, and Extend Pharmaceutical and Biotech Brands 2Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... evolve to survive climate change may depend on the ... mathematical model that simulates the effect of climate change ... early online edition of Evolutionary Applications , are ... change in the past might not be able to ...
... discovered that an active ingredient in the Persian spice saffron ... as multiple sclerosis. Chris Power and a team ... published their findings in the peer-reviewed publication, The Journal ... compound in saffron, known as crocin, that exerts a protective ...
... A new chemical process developed by a team ... Emission Tomography (PET) in creating real-time 3-D images of ... new work by Tobias Ritter, Associate Professor of Chemistry ... possibility of using PET scans to peer into any ...
Cached Biology News:Biodiversity can promote survival on a warming planet 2Medical researchers make important research link between active ingredient in saffron and MS 2Tracing biological pathways 2
Component of HyperMu™ Insertion Kit...
...
Request Info...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Biology Products: